MK 0249

Drug Profile

MK 0249

Alternative Names: MK-0249

Latest Information Update: 28 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Neuropsychotherapeutics
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Obesity; Schizophrenia; Sleep apnoea syndrome

Most Recent Events

  • 01 Jun 2012 Pharmacodynamics data from a phase I trial in Sleep apnoea syndrome reported by Merck
  • 10 Dec 2009 Adverse events data from a clinical trial in healthy subjects presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
  • 12 Dec 2006 Discontinued - Phase-I for Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top